Cargando…
(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
INTRODUCTION: The F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK), a fragment of the human high mobility group protein 2, binds nucleolin. Nucleolin is expressed in the nuclei of normal cells but is also expressed on the membrane of some cancer cells. The goal was to investigate the use of (111)In-labe...
Autores principales: | Cornelissen, Bart, Waller, Andrew, Target, Carol, Kersemans, Veerle, Smart, Sean, Vallis, Katherine A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298710/ https://www.ncbi.nlm.nih.gov/pubmed/22348532 http://dx.doi.org/10.1186/2191-219X-2-9 |
Ejemplares similares
-
Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [(111)In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer
por: Chan, Conrad, et al.
Publicado: (2022) -
Novel [(111)In]In-BnDTPA-EphA2-230-1
Antibody for Single-Photon Emission Computed Tomography Imaging Tracer
Targeting of EphA2
por: Furukawa, Takenori, et al.
Publicado: (2023) -
Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy
por: Kersemans, Veerle, et al.
Publicado: (2010) -
Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, (111)In or β-particle emitting, (177)Lu
por: Aghevlian, Sadaf, et al.
Publicado: (2020) -
[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)